LAB vs BIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 20, 2026

LAB

56.1
AI Score
VS
LAB Wins

BIO

43.3
AI Score

Investment Advisor Scores

LAB

56score
Recommendation
HOLD

BIO

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric LAB BIO Winner
Revenue 41.25M 1.24B BIO
Net Income 100.31M -155.70M LAB
Gross Margin 53.0% 52.7% LAB
Net Margin 243.2% -12.5% LAB
Operating Income -37.88M 106.70M BIO
ROE 18.6% -2.2% LAB
ROA 16.0% -1.5% LAB
Total Assets 627.22M 10.25B BIO
Cash 270.03M 517.00M BIO
Current Ratio 9.10 3.14 LAB
Free Cash Flow -57.82M 144.80M BIO

Relative Price Performance (Last 90 Days)

LAB 1M: -21.8% · 3M: -39.6% BIO 1M: +23.8% · 3M: +31.6%

Current Technical Phase

LAB

Markdown
Sell / avoid

Price below a falling SMA50 (slope -11.9%), weak momentum, RSI 31

RSI (14): 30.5 · Price: $0.64

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.9% over 20 days), RSI 78

RSI (14): 77.8 · Price: $378.91

Fundamentals Snapshot

Metric LAB BIO
Market Cap
Forward P/E -4.0 37.5
Trailing P/E 42.9
Revenue (TTM)
Revenue Growth -0.1% 0.0%
Gross Margin 0.5% 0.5%
Operating Margin -0.4% 0.1%
EPS -0.13 8.49
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, LAB is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.